Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: A comparison of 2 protocols

Archives of Internal Medicine

Volumn 158, Issue 19, 1998, Pages 2155-2159

  Drinka, Paul J ^a,c   Gravenstein, Stefan ^d   Schilling, Margo ^d   Krause, Peggy ^b   Miller, Barbara A ^c   Shult, Peter ^e  

^a Wisconsin Veterans Home   (United States)

^b Research Institute   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; RIMANTADINE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC; HUMAN; INFLUENZA VIRUS A; LONG TERM CARE; MAJOR CLINICAL STUDY; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; VIRUS CULTURE;

AGED; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NURSING HOMES; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RURAL HEALTH; VETERANS; WISCONSIN;

EID: 0032569654     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.19.2155     Document Type: Article

References (16)

1. Center for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP): prevention and control of influenza. MMWR Morb Mortal Wkly Rep. 1990;39:1-15.
2. Dolin R, Reichman RC, Madores P, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580-584.
3. Guay DRP. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging. 1994;5:8-19.
4. Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc. 1991;39:700-705.
5. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): prevention and control of influenza. MMWR Morb Mortal Wkly Rep. 1997;46:1-20.
6. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes. JAMA. 1985;253:1136-1139.
7. Gomolin IH, Leib HB, Arden NH, Sherman FT. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc. 1995;43:71-74.
8. Nicholson KG, Baker DJ, Farquhar A, Hurd D, Kent J, Smith SH. Acute upper respiratory tract viral illness and influenza immunization in homes for the elderly. Epidemiol Infect. 1990;105:609-618.
9. Wald TG, Miler BA, Shult P, Drinka P, Langer L, Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc. 1995;43:170-174.
10. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med. 1997;337:874-880.
11. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol. 1991;134:988-997.
12. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390-392.
13. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Arch Intern Med. 1995;155:533-537.
14. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
15. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696-1702.
16. Drugs for non-HIV viral infections. Med Lett Drugs Ther. 1997;39:69-76.